iRhythm Technologies Adds Two to its Executive Leadership Team

iRhythm Technologies Inc. has appointed two seasoned executives to its leadership team: Brice Bobzien as chief financial officer (CFO) and Reyna Fernandez as executive vice president, chief Human Resources officer.
 
“We are very pleased to welcome Brice and Reyna to our expanded leadership team as we continue to execute upon our vision of building iRhythm into a market leader in the digital healthcare space,” said Quentin Blackford, iRhythm’s president and CEO. “Brice is a veteran executive who brings a wealth of experience building finance teams and guiding organizations through operational transformations. His focus on operational excellence with a disciplined and rigorous approach to financial management and strategic development will position us well for the future. With the addition of Brice into the CFO role, this will allow Doug to focus on the continued improvement of our operational functions that he will continue to lead. Reyna is a seasoned HR executive with over 25 years of experience in building human resource teams, implementing talent development programs, and transforming organizations to operate strategically, globally and efficiently. We look forward to these two successful individuals joining our team to help lead the organization through significant growth with a focus on operational effectiveness and efficiency.”
 
Bobzien most recently served as the senior vice president, Finance & Investor Relations, at Dexcom Inc., where he was responsible for global financial planning and analysis, investor relations, operations accounting, and global pricing strategy. Bobzien played an instrumental role in driving revenue growth initiatives that resulted in the company growing from $700 million to forecasted revenues of approximately $2.9 billion for fiscal year 2022. This growth included the scaling of the company’s global footprint, expanding beyond the United States and into more than 50 countries. During this time, Bobzien transformed the finance team into a world-class organization designed to foster revenue growth and operational discipline. His track record includes more than 20 years of experience and increasing responsibility at leading medical device companies, including Zimmer Holdings Inc., NuVasive Inc. and Dexcom, Inc. Prior to these roles, Bobzien began his career in public accounting.

Bobzien earned a bachelor of science degree in business administration from Indiana University, Fort Wayne, and is a certified public accountant (non-practicing) in Indiana.

Fernandez most recently served as chief Human Resources officer at Intersect ENT Inc., where she was responsible for envisioning and implementing human resources strategies to support the company in becoming an integrated player in the therapeutics space. Fernandez was instrumental in driving the continued growth of Intersect ENT through best-in-class talent acquisition, organizational effectiveness and human capital management functions. During her tenure with the company, she partnered with the CEO and executive leadership to create a performance culture focused on growth and operational excellence, transformed the HR organization to scale globally in line with business objectives, and worked strategically with the board of directors to align on compensation practices. Fernandez brings global experience from her roles with Endologix Inc., Canon Medical Systems USA Inc., Johnson & Johnson, and Bristol-Myers Squibb Company.

Fernandez earned a master’s degree in social administration from Columbia University and a bachelor of arts degree in cultural anthropology from Haverford College in Pennsylvania.
 
iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change the clinical management of patients.